CLINICAL_TRIALS
trial_result
· 2018-12-05
Clinical Trial Update: Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma [Phase 2]
Summary
Phase 2 trial evaluating ibrutinib after stem cell transplantation in double-hit B-cell lymphoma has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2018-12-05